{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:41Z","timestamp":1789578341986,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe public funding of paediatric medications across Canada, including variability between jurisdictions and restrictions based on age or medication formulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted using a list of paediatric medications that was generated from the World Health Organization Pediatric Essential Medicines List and the British Columbia Children's Hospital Drug Dosage Guidelines. Formularies from 14 federal, provincial, and territorial drug plans were analyzed. Data collected included medication listing status, age, and indication-based restrictions, formulation availability, and special authority requirements. Descriptive statistics were used for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On average, 70% of essential paediatric medications were publicly funded in Canada, with significant interjurisdictional variation (35% in Yukon to 87.2% under the Non-Insured Health Benefits [NIHB]). Approximately 13% of medications required special authority. Age- and indication-specific restrictions were uncommon. Funding for paediatric formulations such as liquids and chewables was less available than for tablet and capsule formulations. Territories with unique formulary structures, such as Yukon and Nunavut, showed more limited coverage than other jurisdictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately 20% of paediatric medications lack public funding. There is a geographic disparity in access. Universal pharmacare and mandatory inclusion of paediatric data in drug submissions are needed to ensure equitable access. Findings highlight the urgency for national strategies to close paediatric drug coverage gaps and support consistent, child-friendly medication access across Canada.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pch\/pxag039","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:42:54Z","timestamp":1777030974000},"page":"654-661","source":"Crossref","is-referenced-by-count":0,"title":["Public funding for paediatric medications in Canada"],"prefix":"10.1093","volume":"31","author":[{"given":"Grace","family":"Chen","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia , Vancouver, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junu","family":"Choe","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia , Vancouver, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-8731","authenticated-orcid":false,"given":"Jennifer","family":"Kendrick","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia , Vancouver, BC ,","place":["Canada"]},{"name":"Department of Pharmacy, BC Children's and Women's Hospital , Vancouver, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Carr","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia , Vancouver, BC ,","place":["Canada"]},{"name":"Department of Pharmacy, BC Children's and Women's Hospital , Vancouver, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"9","key":"2026091612564743800_pxag039-B1","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s00431-022-04515-7","article-title":"Off-label use of drugs in pediatrics: A scoping review","volume":"181","author":"Meng","year":"2022","journal-title":"Eur J Ped"},{"issue":"3","key":"2026091612564743800_pxag039-B2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00148581-200810030-00007","article-title":"Documentation of pediatric drug safety in manufacturers' product monographs","volume":"10","author":"Uppal","year":"2008","journal-title":"Pediatr Drugs"},{"issue":"3","key":"2026091612564743800_pxag039-B3","doi-asserted-by":"crossref","first-page":"E522","DOI":"10.9778\/cmajo.20200010","article-title":"Pediatric drug data in Canadian drug monographs: A descriptive analysis","volume":"8","author":"Raja","year":"2020","journal-title":"CMAJ Open"},{"issue":"3","key":"2026091612564743800_pxag039-B4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/bcp.15553","article-title":"Does EU and US paediatric legislation improve the authorization availability of medicines for children in other countries?","volume":"89","author":"Volodina","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2026091612564743800_pxag039-B5","first-page":"54","article-title":"Reforming paediatric drug regulations in Canada: A clinical and an access imperative","volume":"19","author":"Hepburn","year":"2023","journal-title":"Healthc Policy"},{"issue":"4","key":"2026091612564743800_pxag039-B6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4212\/cjhp.v73i4.3023","article-title":"Providing suitable pediatric formulations for Canadian children: A call to action","volume":"73","author":"Litalien","year":"2020","journal-title":"Can J Hosp Pharm"},{"key":"2026091612564743800_pxag039-B7","author":"World Health Organization Model List of Essential Medicines for Children"},{"key":"2026091612564743800_pxag039-B8","volume-title":"BC Children's Hospital Pediatric Drug Dosage Guidelines","author":"Kendrick","year":"2021","edition":"8th ed"},{"key":"2026091612564743800_pxag039-B9","first-page":"162","article-title":"Breadth, depth and agreement among provincial formularies in Canada","volume":"4","author":"Morgan","year":"2009","journal-title":"Healthc Policy"},{"issue":"1","key":"2026091612564743800_pxag039-B10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40545-015-0043-5","article-title":"Policy versus practice: A community-based qualitative study of the realities of pharmacy services in Nunavut, Canada","volume":"8","author":"Romain","year":"2015","journal-title":"J Pharm Policy Pract"},{"issue":"3","key":"2026091612564743800_pxag039-B11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.healthpol.2022.01.012","article-title":"Variability in prescription medication coverage for children and youth across Canada: A scoping review","volume":"126","author":"Ahmad","year":"2022","journal-title":"Health Policy"},{"key":"2026091612564743800_pxag039-B12","author":"Aoun"},{"key":"2026091612564743800_pxag039-B13","first-page":"100","article-title":"Public drug plan coverage for children across Canada: A portrait of too many colours","volume":"1","author":"Ungar","year":"2005","journal-title":"Healthc Policy"},{"key":"2026091612564743800_pxag039-B14","author":"McLaughlin"},{"key":"2026091612564743800_pxag039-B15","author":"Hepburn"},{"issue":"19","key":"2026091612564743800_pxag039-B16","doi-asserted-by":"crossref","first-page":"E678","DOI":"10.1503\/cmaj.220044","article-title":"Time for a regulatory framework for pediatric medications in Canada","volume":"194","author":"Gilpin","year":"2022","journal-title":"CMAJ"},{"key":"2026091612564743800_pxag039-B17","author":"Health Canada. Government of Canada"}],"container-title":["Paediatrics &amp; Child Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pch\/article-pdf\/31\/6\/654\/68508729\/pxag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pch\/article-pdf\/31\/6\/654\/68508729\/pxag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:56:55Z","timestamp":1789577815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pch\/article\/31\/6\/654\/8705591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,11]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/pch\/pxag039","relation":{},"ISSN":["1205-7088","1918-1485"],"issn-type":[{"value":"1205-7088","type":"print"},{"value":"1918-1485","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,6,11]]}}}